Head-to-head evidence
Crexont (IPX203) vs WD-1603
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: December 2026 · NCT07138560 (registry estimate)
WD-1603
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · WD-1603's landscape